Many drugmakers ignore Trump — and raise prices anyway

By Robert Langreth and Cynthia Koons
Published 6 Min Read

Prices are soaring for specialty drugs used to treat critical illnesses such as cancer, Hepatitis C and multiple sclerosis, as well as more common conditions like high cholesterol. Right now, employers are largely bearing the brunt of the cost, and health care experts and leading employer organizations like the Minnesota Health Action Group are looking for collaborative, sustainable, solutions to this challenging situation.

Robert Langreth and Cynthia Koons
From Bloomberg

For reprint and licensing requests for this article, click here.


More From Employee Benefit News

Sign Up Form

Login Modal Form